QUILT-3.055: A Phase 2b, Single-Arm, Multicohort, Open-Label Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment with PD-1/PD-L1 Immune Checkpoint Inhibitors. DRUGS: N-803 (aka ALT-803) + PD-L1 t-haNK suspension for infusion
This study is designed to treat multiple solid tumor cancers. This type of study is done because of how the drug is expected to work against cancer. This study will enroll patients who have been diagnosed with any of the following cancers:
- Lung Cancer
- Bladder Cancer
- Head & Neck Cancer
- Kidney Cancer
- Merkel Cell Carcinoma
- Gastric Cancer
- Cervical Cancer
- Liver Cancer
- Colon Cancer
Another eligibility criterion requires prior treatment with a checkpoint inhibitor. Checkpoint inhibitors are immunotherapy drugs that help the immune system to target and kill cancer cells. The checkpoint inhibitors include: pembrolizumab (Keytruda), nivolumab (Opdivo), avelumab (Bavencio), atezolizumab (Tecentriq), and durvalumab (Imfinzi).
The QUILT 3.055 study uses various immunotherapies in combination with a new drug called N-803. These immunotherapies when combined work synergistically and in multiple mechanisms for the treatment of these cancers. Synergism means that the drugs interact with each other to produce a combined effect greater than what they could do by themselves. Immunotherapies are an effective and well tolerated treatment for lung cancer. N-803 is a new type of immunotherapy that is showing very promising results so far.
If you are interested in more information on this study, please contact us. Refer to the QUILT 3.055 study. You can also find information on this study by going to clinicaltrials.gov website and searching for NCT 03228667.